Chemically Programmable and Switchable CAR-T Therapy

被引:35
|
作者
Qi, Junpeng [1 ]
Tsuji, Kohei [2 ,3 ]
Hymel, David [2 ]
Burke, Terrence R., Jr. [2 ]
Hudecek, Michael [4 ]
Rader, Christoph [1 ]
Peng, Haiyong [1 ]
机构
[1] Scripps Res Inst, Dept Immunol & Microbiol, 130 Scripps Way, Jupiter, FL 33458 USA
[2] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Bldg 376 Boyles St, Frederick, MD 21702 USA
[3] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Dept Med Chem, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan
[4] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacherstr 6, D-97080 Wurzburg, Germany
基金
美国国家卫生研究院;
关键词
antibodies; antitumor agents; cell-surface receptors; CAR-Ts; immunotherapy; BISPECIFIC ANTIBODIES; ALDOLASE ANTIBODY; FOLATE RECEPTOR; CELLS; IMMUNOTHERAPY; MOLECULES; SELECTION; STRATEGY;
D O I
10.1002/anie.202005432
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Although macromolecules on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small molecules and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility. Compared to antibodies, however, small molecules are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system. Presented herein is a method that endows small molecules with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts). It is based on a CAR-T platform that uses a chemically programmed antibody fragment (cp-Fab) as on/off switch. In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.
引用
收藏
页码:12178 / 12185
页数:8
相关论文
共 50 条
  • [31] A Novel Switchable CAR-T Platform for Acute Lymphoblastic Leukemia Treatment
    Laborda, Eduardo
    Hampton, Eric N.
    Lee, Sung C.
    Woods, Ashley K.
    Young, Travis S.
    BLOOD, 2017, 130
  • [32] CAR-T cell therapy for T cell malignances
    Watanabe, Keisuke
    CANCER SCIENCE, 2025, 116 : 1784 - 1784
  • [33] CAR-T cell therapy for T cell malignances
    Watanabe, Keisuke
    CANCER SCIENCE, 2024, 115 : 812 - 812
  • [34] CARDIAC LYMPHOMA MANAGED WITH CAR-T THERAPY
    Bonilla, Hilda M. Gonzalez
    Ng, Choon-Ta
    Gile, Jennifer
    Chang, Ian
    Lin, Grace
    Herrmann, Joerg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2458 - 2458
  • [35] CAR-T Therapy Complicated by Cavitary CMV
    Menon, D. Padmanabhan
    Debella, Y. T.
    Marin-Acevedo, J. A.
    Fernandez-Bussy, S.
    Mira-Avendano, I. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [36] Teaming up for CAR-T cell therapy
    Waesch, Ralph
    Munder, Markus
    Marks, Reinhard
    HAEMATOLOGICA, 2019, 104 (12) : 2335 - 2336
  • [37] Leukapheresis for CAR-T cell production and therapy
    Pessach, Ilias
    Nagler, Arnon
    TRANSFUSION AND APHERESIS SCIENCE, 2023, 62 (06)
  • [38] Advances in Universal CAR-T Cell Therapy
    Lin, Haolong
    Cheng, Jiali
    Mu, Wei
    Zhou, Jianfeng
    Zhu, Li
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [39] Nonlinear dynamics of CAR-T cell therapy
    Fassoni, Artur C.
    Braga, Denis C.
    CHAOS SOLITONS & FRACTALS, 2025, 191
  • [40] NUTRITIONAL IMPLICATIONS OF CAR-T THERAPY IN SCOTLAND
    Dean, Abigail
    BONE MARROW TRANSPLANTATION, 2024, 59 : 686 - 686